[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369247-105":59,"doc-detail-369247-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","comprehensive-genome-profiling-initiated-tumor-informed-circulating-tumor-dna-monitoring-for-patients-with-advanced-cancer","Comprehensive Genome Profiling-Initiated Tumor-Informed Circulating Tumor DNA Monitoring for Patients With Advanced Cancer","","In Japan, comprehensive genome profiling (CGP) as a companion diagnostic has been covered by public insurance since June 2019, yet only a small fraction of patients receive drug therapy based on CGP findings. This retrospective study validated CGP as a starting point for tumor-informed circulating tumor DNA (ctDNA) monitoring in 219 advanced cancer patients treated at Iwate Medical University between 2019 and 2023.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comprehensive-genome-profiling-initiated-tumor-informed-circulating-tumor-dna-monitoring-for-patients-with-advanced-cancer/369247/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comprehensive-genome-profiling-initiated-tumor-informed-circulating-tumor-dna-monitoring-for-patients-with-advanced-cancer/369247.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why was this study conducted regarding CGP and ctDNA monitoring?","Question",{"text":112,"@type":113},"Although CGP is covered as a companion diagnostic in Japan, few patients receive drug therapy based on CGP data. The study evaluated CGP as a starting point for tumor-informed ctDNA monitoring.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many patients were retrospectively validated, and what time window was used?",{"text":117,"@type":113},"The study retrospectively validated 219 patients who underwent CGP at Iwate Medical University Hospital between October 2019 and April 2023.",{"name":119,"@type":110,"acceptedAnswer":120},"What clinical validity outcomes were assessed for ctDNA monitoring based on CGP-identified somatic mutations?",{"text":121,"@type":113},"Clinical validity was assessed through early relapse prediction, treatment response evaluation, and confirmation of no relapse/regrowth.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369247,1790331653,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Cancer Science  \nORIGINAL ARTICLE  OPEN ACCESS   \nComprehensive Genome Profiling-Initiated  \nTumor-Informed Circulating Tumor DNA Monitoring for Patients With Advanced Cancer  \nTaiga Sasaki1,2  | Hayato Hiraki1 | Akiko Yashima-Abo1 | Hiromi Nagashima2 | Fumitaka Endo3 | Mizunori Yaegashi4 | Shimpei Miura5 | Keiko Obata6 | Naoki Yanagawa7 | Hiroaki Itamochi3  | Hidekazu Shirota8  |  \nTakeshi Iwaya3 | Satoshi S. Nishizuka1   \n1Division of Biomedical Research and Development, Iwate Medical University Institute for Biomedical Sciences, Yahaba, Japan | 2Department of Respiratory Medicine, Iwate Medical University School of Medicine, Yahaba, Japan | 3Department of Clinical Oncology, Iwate Medical University School of Medicine, Yahaba, Japan | 4Department of Surgery, Iwate Medical University School of Medicine, Yahaba, Japan | 5Department of Dermatology, Iwate Medical University School of Medicine, Yahaba, Japan | 6Department of Clinical Genetics, Iwate Medical University School of Medicine, Yahaba, Japan | 7Department of Diagnostic Pathology, Iwate Medical University School of Medicine, Yahaba, Japan | 8Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan  \nCorrespondence: Satoshi S. Nishizuka ([snishizu@iwate-med.ac.jp](snishizu@iwate-med.ac.jp))  \nReceived: 14 November 2024 | Accepted: 21 December 2024  \nFunding: This work was supported by Japan Society for the Promotion of Science (Grant/Award Number: 21K07223), Japan Agency for Medical Research and Development (Grant/Award Number: 24ck0106825h0002) .  \nKeywords: comprehensive genome profiling | Digital PCR | tumor-informed ctDNA monitoring  \nABSTRACT  \nIn Japan, comprehensive genome profiling (CGP) as a companion diagnostic (CDx) has been covered by public insurance since June 2019, but the proportion of patients with cancer who actually received drug therapy based on CGP data is low. In the present study, we attempted to use CGP as a starting point for tumor-informed circulating tumor DNA (ctDNA) monitoring. We retrospectively validated 219 patients with malignant tumors who underwent CGP at Iwate Medical University Hospital between October 2019 and April 2023 in terms of patient demographics, genetic analysis, drug recommendations, and drug administration rate. The 219 cancer cases analyzed by CGP for 27 target organs, including prostate (n = 27, 12.3%), colorectal (n = 25, 11.4%), lung (n = 19, 8.7%), and other neoplasms (n = 148, 67.6%). Among the cohort, only 14 cases (6.4%) subsequently were able to undertake the recommended action by Molecular Tumor Board. Of patients who underwent ctDNA monitoring based on somatic mutations identified by CGP (n = 11), clinical validity was confirmed in terms of early relapse prediction (n = 5, 45.5%), treatment response evaluation (n = 10, 90.9%), and no relapse/regrowth corroboration (n = 2, 18.2%) whereas 90.9%(n = 10) of patients obtained information with at least one source of the clinical validity. Although the current rate of CGP contributing to a drug recommendation is low, CGP results can be an alternate resource for tumor-informed longitudinal ctDNA monitoring to provide information concerning early relapse prediction, treatment response evaluation, and no relapse/regrowth corroboration.  \n\n| Abbreviations: BDL, below detection limit; BEV, bevacizumab; CDx, companion diagnostics; CGP, comprehensive genome profile; CHIP, clonal hematopoiesis of indeterminate potential; CNV, copy number variation; ctDNA, circulating tumor deoxyribonucleic acid; dPCR, digital polymerase chain reaction; F1, FoundationOneⓇCDx; F1L, FoundationOneⓇLiquid CDx; FDG, 18F-fluorodeoxyglucose; FFPE, formalin-fixed paraffin-embedded; G360, Guardant 360Ⓡ CDx; Indel, insertion/deletion; jMorp, Japanese Multi Omics Reference Panel; LB, liquid biopsy; MSI, microsatellite instability; MSS, microsatellite stable; MTB, molecular tumor board; NGS, next-generation sequencing; NOP, Oncoguide NCC Oncopanel System; OTS, off-the-shelf; PD, progressive","cbCaisZJaCgqsAzA","https://ap.wps.com/l/cbCaisZJaCgqsAzA","pdf",1625829,11,"English","# Abstract\n# Introduction","[{\"question\":\"Why was this study conducted regarding CGP and ctDNA monitoring?\",\"answer\":\"Although CGP is covered as a companion diagnostic in Japan, few patients receive drug therapy based on CGP data. The study evaluated CGP as a starting point for tumor-informed ctDNA monitoring.\"},{\"question\":\"How many patients were retrospectively validated, and what time window was used?\",\"answer\":\"The study retrospectively validated 219 patients who underwent CGP at Iwate Medical University Hospital between October 2019 and April 2023.\"},{\"question\":\"What clinical validity outcomes were assessed for ctDNA monitoring based on CGP-identified somatic mutations?\",\"answer\":\"Clinical validity was assessed through early relapse prediction, treatment response evaluation, and confirmation of no relapse/regrowth.\"}]","Comprehensive Genome Profiling-Initiated Tumor-Informed Circulating Tumor DNA Monitoring for Patients With Advanced Cancer | PDF",1790181602,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/837a4974653aeb613a6c74bd4d0626de.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d57807e5fb77d76fc6a6521513c40b9.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/761cb851a9c0ddaf82a291407ff3919d.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0169a858013e98be78ce52de5c3740b8.webp",980,1287]